Predictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Breast cancer is the most common female malignancy globally.
• Novel targeted therapies and immunotherapies offer new hope for treatment-resistant patients.
• Current novel therapies include CDK4/6, PARP, PI3K inhibitors, ADCs, and PD-1 inhibitors.

Purpose of the Study:

• To review existing predictive biomarkers for breast cancer treatments.
• To highlight recent advancements in identifying biomarkers for novel therapies.
• To address the challenge of predicting patient response to targeted agents and immunotherapies.

Main Methods:

• Literature review of current and emerging predictive biomarkers.
• Analysis of clinical applications of targeted therapies and immunotherapies.
• Synthesis of research on biomarker discovery for breast cancer.

Main Results:

• Several targeted therapies (e.g., CDK4/6 inhibitors) and immunotherapies (e.g., PD-1 inhibitors) are in clinical use.
• Predictive biomarkers are essential but their identification and validation remain challenging.
• Ongoing research focuses on discovering more accurate markers for personalized treatment selection.

Conclusions:

• Accurate predictive biomarkers are critical for maximizing the efficacy of novel breast cancer therapies.
• Further research is needed to validate new biomarkers for targeted therapies and immunotherapies.
• Personalized medicine approaches in breast cancer rely heavily on robust biomarker strategies.